Viking leads a $46M raise for a strug­gling aTyr Phar­ma

With its share price in a swoon, San Diego-based aTyr Phar­ma $LIFE has inked a $46 mil­lion eq­ui­ty deal to fund its de­vel­op­ment work. Viking Glob­al In­vestors led the raise with par­tic­i­pa­tion from EcoR1 Cap­i­tal and Red­mile Group. The group bought shares at $2.64.

Shares came close to $23 each in the spring of 2015, af­ter the biotech went pub­lic at $14 a share. But the glo­ry days didn’t last long, with the stock falling steadi­ly. The biotech’s mar­ket cap start­ed at $333 mil­lion; it’s now down to $63 mil­lion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.